List of Excipients in Branded Drug NALMEFENE HYDROCHLORIDE

Generic Drugs Containing NALMEFENE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Knoa Pharma LLC	nalmefene hydrochloride	59011-960	HYDROCHLORIC ACID
Knoa Pharma LLC	nalmefene hydrochloride	59011-960	SODIUM CHLORIDE
Knoa Pharma LLC	nalmefene hydrochloride	59011-960	WATER

What are the Most Frequently-Used Excipients in NALMEFENE HYDROCHLORIDE?

# Of NDCs	Excipient
2	HYDROCHLORIC ACID
2	SODIUM CHLORIDE
2	WATER

Last updated: September 24, 2026

Nalmefene hydrochloride has three commercial formulation pathways: oral tablets for alcohol-use-disorder treatment, intranasal spray for community opioid rescue, and injectable products for emergency medical use. The strongest near-term excipient opportunities are in unit-dose nasal delivery, low-temperature-stable emergency injections, preservative-free presentations, and cost-reduced oral tablets. Product differentiation depends more on device performance, stability, human factors, and regulatory evidence than on the active ingredient itself.

Nalmefene Hydrochloride Excipient Strategy and Commercial Opportunities

What products contain nalmefene hydrochloride?

Nalmefene hydrochloride is a long-acting opioid receptor antagonist structurally related to naltrexone. Approved products use different dosage forms because the commercial objectives differ.

Product	Sponsor	Route	Strength	Primary use	Regulatory status
Selincro	H. Lundbeck / Otsuka in certain markets	Oral tablet	18 mg nalmefene equivalent	Reduction of alcohol consumption in alcohol dependence	Authorized in the European Union and other markets
Opvee	Indivior	Intranasal spray	2.7 mg per 0.1 mL spray	Emergency treatment of known or suspected opioid overdose	FDA-approved in 2023
Zurnai	Purdue Pharma / Imbrium-related commercial interests	Autoinjector	1.5 mg per 0.5 mL	Emergency treatment of opioid overdose	FDA-approved in 2024
Earlier injectable nalmefene products	Various	Intravenous or intramuscular injection	Multiple strengths	Opioid overdose reversal	Historical or limited commercial status

The FDA approved Opvee as a prescription nasal spray for patients age 12 and older and Zurnai as a single-dose autoinjector for emergency treatment of opioid overdose. Both products address the longer duration of action of nalmefene compared with naloxone, although the longer pharmacology also creates concerns about prolonged opioid withdrawal and adverse effects.[1,2]

What excipients are used in nalmefene hydrochloride products?

Excipients vary by route. The commercial formulation problem is different for a tablet, a nasal spray, and an emergency injection.

Oral tablet excipients

Selincro contains nalmefene hydrochloride dihydrate equivalent to 18 mg of nalmefene. The tablet platform uses conventional solid-dose excipients, including:

• Mannitol as a diluent
• Microcrystalline cellulose as a compression aid
• Crospovidone and low-substituted hydroxypropylcellulose as disintegrants
• Magnesium stearate as a lubricant
• Hypromellose, polyethylene glycol, and titanium dioxide in the film coating

The oral formulation is technically straightforward. Its value lies in dose uniformity, rapid disintegration, acceptable taste and swallowability, and stability under ordinary pharmacy conditions. The most commercially relevant opportunities are therefore cost reduction, regional excipient substitution, modified-release development, and formulation work intended to reduce gastrointestinal effects.

Nalmefene has high oral bioavailability relative to many opioid antagonists, which reduces the need for an aggressive absorption-enhancement system. A conventional immediate-release tablet is usually more defensible from a regulatory and manufacturing perspective than a complex delivery platform.[3]

Intranasal spray excipients

Opvee uses an aqueous nasal formulation. Its inactive ingredients include buffering agents, tonicity or bulking components, a preservative system, and water for injection. The label identifies excipient components including mannitol, citric acid monohydrate, sodium citrate dihydrate, benzalkonium chloride, and disodium edetate dihydrate.[1]

The formulation objectives are narrow:

1. Maintain nalmefene hydrochloride in solution.
2. Control pH and osmolality.
3. Limit nasal irritation.
4. Preserve spray performance across storage and temperature excursions.
5. Support consistent delivery from a compact unit-dose device.
6. Control microbial risk during the labeled shelf life.

Mannitol can support tonicity and formulation robustness. Citrate provides buffer capacity. Benzalkonium chloride supplies antimicrobial preservation, while disodium edetate can improve preservative performance by binding trace metals and reducing degradation pathways.

The main excipient risk is local tolerability. A nasal product intended for repeated use in public emergencies must minimize burning, sneezing, congestion, and mucosal irritation. Preservatives may improve microbiological robustness but can constrain long-term nasal tolerability. This creates an opportunity for preservative-free unit-dose products if the packaging system provides adequate sterility assurance and the sponsor can demonstrate equivalent performance.

Injectable and autoinjector excipients

Zurnai is supplied as a sterile solution for injection in a single-dose autoinjector. Its formulation uses a simple aqueous vehicle with sodium chloride for tonicity adjustment and pH adjustment using hydrochloric acid and/or sodium hydroxide.[2]

This is an important formulation choice. An emergency injectable product should avoid unnecessary excipient complexity because every additional component increases the potential for:

• Injection-site reactions
• Container-closure interaction
• Visible or subvisible particles
• Oxidative or hydrolytic degradation
• Regulatory comparability work
• Supply-chain failures

For injectable nalmefene, the device and container are as important as the excipient package. Commercial development should focus on low extractables and leachables, autoinjector force consistency, needle deployment reliability, freezing tolerance, and shelf-life maintenance after temperature cycling.

Which excipient strategy is best for intranasal nalmefene?

A buffered, isotonic, preservative-controlled aqueous spray is the most practical platform for emergency intranasal nalmefene. The formulation should prioritize nasal tolerability and spray reproducibility over high drug loading.

A competitive formulation program would evaluate:

Formulation variable	Commercial objective	Key development risk
Citrate or phosphate buffer	Maintain pH during shelf life	Irritation and buffer capacity
Mannitol or sodium chloride	Control osmolality	Crystallization or sensory effects
Benzalkonium chloride	Microbial preservation	Chronic mucosal tolerability
EDTA or alternative chelator	Improve stability and preservative performance	Compatibility and regulatory justification
Preservative-free design	Improve tolerability and simplify repeat-use positioning	Sterility and packaging cost
Pump or spray actuator	Deliver a reproducible 0.1 mL dose	Plume geometry and human-factor failure
Low-viscosity solution	Support rapid absorption and reliable actuation	Leakage and dose variability
Higher-viscosity system	Improve retention on nasal mucosa	Slower spray formation and device compatibility

A mucoadhesive platform may appear attractive, but it can create tradeoffs. Increased viscosity can reduce runoff and improve residence time, yet it may impair atomization, alter absorption, or increase device variability. A mucoadhesive excipient would need a clear clinical benefit because the established product already uses a rapid-acting aqueous spray.

What formulation patents protect nalmefene products?

The active pharmaceutical ingredient has limited patent value because nalmefene was discovered and disclosed decades ago. The principal defensible areas are formulation, delivery device, manufacturing process, and emergency-use positioning.

Nasal formulation patents

Potentially valuable claims include:

• Nalmefene hydrochloride in a defined concentration range
• pH and osmolality windows
• Specific buffer and preservative combinations
• Stabilized aqueous solutions
• Unit-dose nasal spray containers
• Spray plume and droplet-size specifications
• Use in opioid overdose involving potent synthetic opioids
• Repeat dosing or administration instructions

A formulation patent is strongest when it links composition to measurable performance, such as improved stability, lower nasal irritation, consistent delivered dose, or rapid pharmacokinetic exposure. Broad claims covering ordinary aqueous buffers and preservatives are more vulnerable to invalidity or design-around strategies.

Device and combination-product patents

The nasal pump, actuator, container, and dose-metering system can create a separate patent layer. Relevant claims may cover:

• Actuator geometry
• Dose-metering chambers
• Protection against accidental discharge
• Child-resistant packaging
• Unit-dose packaging
• Spray angle and plume geometry
• Integration of the drug container with an emergency-use device

Device claims can delay direct substitution even when the drug formulation itself is simple. A generic or 505(b)(2) applicant would need to assess whether it can use a different spray pump and still demonstrate equivalent delivery and clinical performance.

Injectable and autoinjector patents

For autoinjectable nalmefene, commercial protection may arise from:

• Pre-filled syringe configuration
• Needle-shield design
• Automatic needle deployment
• Dose delivery confirmation
• Temperature-resistant packaging
• Human-factors architecture
• Combination of nalmefene with a specific emergency-use device

The manufacturing process can also create barriers. Sterile filling, particulate control, container-closure integrity, and device assembly require specialized facilities. These are practical barriers even where composition claims are narrow.

When does nalmefene lose exclusivity?

Nalmefene’s original compound protection is no longer the principal commercial barrier. Exclusivity depends on product-specific patents, regulatory exclusivity, and device protection.

Exclusivity category	Strategic relevance
Original compound patent	Generally expired or commercially weak
Oral tablet formulation	Limited protection unless supported by new formulation claims
Nasal spray formulation	Potentially meaningful where claims cover composition and delivery
Autoinjector	Potentially meaningful because device and combination-product claims can block simple substitution
Orphan-drug exclusivity	Not the central protection for current nalmefene overdose products
New chemical entity exclusivity	Unlikely to provide current U.S. protection because nalmefene is an old active ingredient
Pediatric exclusivity	Product-specific and dependent on FDA-awarded studies
Patent-term extension	Must be evaluated against each listed patent and approval

The FDA Orange Book should be reviewed product by product for listed patents and regulatory exclusivity. Orange Book listing is most important for approved drug products subject to abbreviated applications. Device-only rights and unlisted formulation or manufacturing patents may remain commercially relevant even when they do not appear in the Orange Book.[4]

What is the Orange Book and Paragraph IV status of nalmefene?

A Paragraph IV challenge would be most likely against an approved product with listed formulation or delivery patents, particularly Opvee or Zurnai. The commercial outcome would depend on the challenger’s proposed route, device, formulation, and labeling.

A prospective ANDA or 505(b)(2) applicant would evaluate:

• Whether the reference product has listed patents
• Whether the applicant can use a different excipient system
• Whether the applicant can avoid the reference device
• Whether nasal deposition and delivered dose are equivalent
• Whether a section viii statement can omit protected method-of-use language
• Whether the proposed product requires a new clinical bridge
• Whether the reference product has orphan or pediatric exclusivity

For intranasal nalmefene, a pure ANDA pathway may be more difficult than for a conventional tablet because the device is part of the product’s performance profile. A 505(b)(2) pathway could be more flexible for a different nasal pump, preservative-free formulation, alternative concentration, or new emergency-use presentation.

No commercial strategy should assume that a compositionally different product avoids all patent exposure. Device, use, process, and packaging claims can remain relevant after a formulation design-around.

Which companies are challenging the nalmefene market?

The principal competitive threat is not another nalmefene product. It is the established naloxone market.

Competitor	Product type	Competitive advantage
Emergent BioSolutions	Narcan nasal spray	Established public recognition and broad distribution
Hikma Pharmaceuticals	Naloxone injection	Hospital and emergency-use presence
Sandoz and other generic manufacturers	Naloxone products	Lower price and broad institutional access
Indivior	Opvee	Longer-acting nalmefene and intranasal delivery
Purdue-related commercial interests	Zurnai	Autoinjector format and emergency-use positioning
Lundbeck / regional partners	Selincro	Established oral alcohol-use-disorder indication

Nalmefene’s commercial argument is duration. Its disadvantage is the possibility of longer-lasting withdrawal after opioid reversal. For a purchaser, the value proposition depends on the setting. A public-access program may favor a familiar, low-cost naloxone product. A first-responder, correctional, military, or high-potency synthetic-opioid program may value longer activity and an alternative rescue mechanism.

What commercial opportunities exist for nalmefene hydrochloride excipients?

Preservative-free nasal rescue products

A preservative-free unit-dose spray could target repeat-use environments and users concerned about nasal irritation. The main opportunity is not merely excipient replacement. It is the combination of a sterile or microbiologically controlled container with a device that maintains dose accuracy.

Improved nasal tolerability

A lower-irritation buffer and osmolality system could support differentiation if it demonstrates less local discomfort without slowing absorption. This would require comparative clinical or pharmacodynamic evidence, not only laboratory data.

Temperature-stable emergency products

Emergency medicines may be stored in vehicles, public-access cabinets, schools, shelters, and outdoor locations. Excipient systems that reduce degradation during heat and freeze-thaw exposure can create value even without a new active ingredient.

Lower-cost oral tablets

For alcohol-use-disorder treatment, a generic or regional tablet supplier could compete through lower-cost excipients, simplified coating systems, and locally qualified sources. The regulatory burden is materially lower than for a nasal combination product, but market size and treatment uptake may also be smaller.

Pediatric and adolescent presentations

Opvee is approved for patients age 12 and older. Opportunities may include packaging, labeling, and administration systems designed for schools, youth services, and caregivers. A lower delivered dose would require careful pharmacokinetic and clinical justification because underdosing is unacceptable in opioid overdose.

Manufacturing and supply-chain services

Commercial opportunities exist for:

• Sterile nasal filling
• Unit-dose pump assembly
• Pre-filled autoinjector assembly
• Extractables and leachables testing
• Stability-indicating analytical methods
• Device-performance testing
• Excipient qualification
• Cold-chain and accelerated-stability programs

These capabilities can have greater commercial value than a novel excipient because nalmefene products are combination products with demanding emergency-use requirements.

How strong is the nalmefene hydrochloride patent estate?

The estate is strongest around branded delivery systems and weakest around the active ingredient and conventional tablet chemistry.

Area	Relative strength	Reason
Nalmefene molecule	Low	Old active ingredient
Standard oral tablet	Low to moderate	Conventional excipient technology
Aqueous nasal formulation	Moderate	Possible composition and stability claims
Nasal spray device	Moderate to strong	Device performance can be difficult to design around
Autoinjector	Moderate to strong	Combination-product and human-factors protection
Emergency-use method claims	Moderate	Commercial value depends on enforceability and labeling
Sterile manufacturing process	Moderate	Practical barrier, but process claims may be narrow
Excipient-specific claims	Variable	Strong only when linked to unexpected performance

Geographic coverage is likely to differ by product. U.S. protection is most important for Opvee and Zurnai. Selincro’s commercial protection is evaluated separately across European and other national jurisdictions. Patent term, prosecution history, regulatory exclusivity, and litigation records must be assessed in each country rather than inferred from U.S. status.

What patent litigation and settlement risks affect nalmefene?

The largest litigation risk would arise from an abbreviated applicant challenging nasal formulation, spray-device, or autoinjector patents. Likely disputes would concern:

• Obviousness of the excipient combination
• Written description and enablement
• Claim construction for delivered-dose and spray-performance terms
• Whether the reference product’s device is claimed
• Whether a proposed formulation is substantially equivalent
• Whether method-of-use claims are properly carved out
• Whether the patent claims cover the approved commercial configuration

Settlement structures could include delayed launch, authorized generic supply, license rights for specific territories, or access to a non-infringing device platform. Because nalmefene is an old molecule, settlement value would depend primarily on the remaining life of delivery and device patents, not on the active ingredient.

How does nalmefene compare with naloxone?

Attribute	Nalmefene	Naloxone
Pharmacology	Longer-acting opioid antagonist	Shorter-acting opioid antagonist
Overdose use	FDA-approved nasal and injectable products	Broadly established nasal and injectable products
Main benefit	Potentially longer protection against recurrent respiratory depression	Extensive clinical familiarity and broad availability
Main risk	Longer or more severe precipitated withdrawal	Recurrent toxicity after naloxone wears off
Formulation opportunity	Nasal, autoinjector, sterile emergency products	Large generic and branded ecosystem
Pricing pressure	Currently limited relative to mature naloxone	High due to generic competition
Patent opportunity	Device and formulation focused	Mostly product-specific devices and formulations

Nalmefene has an opportunity in settings where duration, alternative opioid-reversal options, or device differentiation justify a premium. Naloxone remains the stronger benchmark for procurement scale, familiarity, and price.

Key Takeaways

• Nalmefene hydrochloride has the best commercial opportunity in emergency nasal and autoinjector products, not in the old active ingredient.
• The most important excipient issues are nasal tolerability, pH, osmolality, preservative strategy, stability, and device compatibility.
• A preservative-free unit-dose nasal spray is a credible formulation opportunity but requires strong sterility and device evidence.
• Conventional oral tablets offer lower technical risk but likely face lower market growth and greater generic substitution.
• Patent value is concentrated in formulation, delivery device, manufacturing, packaging, and emergency-use claims.
• Paragraph IV exposure is most relevant to products with listed nasal or autoinjector patents.
• Nalmefene competes primarily against naloxone, so commercial success depends on proving value from longer duration rather than relying on molecule novelty.
• Sterile manufacturing, device assembly, and stability programs are attractive commercial services supporting nalmefene development.

FAQs

Can mannitol be replaced in nalmefene nasal spray?

Yes. Potential substitutes include sodium chloride or other tonicity-adjusting systems, but the replacement must preserve pH, osmolality, spray performance, chemical stability, and nasal tolerability.

Is benzalkonium chloride essential in nalmefene nasal spray?

No. It is a preservative option, not an unavoidable component. A preservative-free unit-dose system could avoid it, provided the packaging and microbiological-control strategy are adequately validated.

Is nalmefene hydrochloride suitable for an orally disintegrating tablet?

Potentially. An orally disintegrating tablet could improve administration for patients with impaired cooperation, but taste masking, dose uniformity, moisture control, and rapid disintegration would become central development issues.

Does a different nasal pump avoid Opvee patents?

Not necessarily. A different pump may avoid specific device claims, but formulation, concentration, method-of-use, spray-performance, and packaging claims could still apply.

Is a nalmefene generic likely to be cheaper than naloxone?

Not automatically. Nalmefene products may have higher manufacturing and device costs, particularly for autoinjectors and specialized nasal pumps. Price competition would increase as multiple suppliers enter and device components become standardized.

References

1. U.S. Food and Drug Administration. (2023). Opvee (nalmefene hydrochloride) nasal spray prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Zurnai (nalmefene hydrochloride) injection prescribing information. FDA.

3. European Medicines Agency. (2024). Selincro: EPAR product information. EMA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.